Eysys Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 5.80%
- Profit Growth -32.48%
- Ebitda -99.19%
- Net Worth 46.86%
- Total Assets -0.50%
About Eysys Pharmaceutical
Eysys Pharmaceutical Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 August 2019 (Five years and six months 21 days old ). Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Raveendran Ratheesh, Mani Deepakkumar, and Manian Jayakrishnan serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230TN2019PTC130992
- Company No.
130992
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Eysys Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raveendran Ratheesh  | Managing Director | 07-Aug-2019 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mani Deepakkumar | Director | 07-Aug-2019 | Current |
| Manian Jayakrishnan | Director | 07-Aug-2019 | Current |
Financial Performance of Eysys Pharmaceutical.
Eysys Pharmaceutical Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.8% increase. The company also saw a substantial fall in profitability, with a 32.48% decrease in profit. The company's net worth Soared by an impressive increase of 46.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eysys Pharmaceutical?
In 2023, Eysys Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eysys Pharmaceutical?
Eysys Pharmaceutical has a workforce of 58 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eysys Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eysys Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.